The rationale for universal use of a prophylactic Epstein-Barr virus vaccine.
Level 5 - mechanism / opinion, no new human data
Narrative review and commentary with no original human data or systematic synthesis
PubMed 42214819 · doi:10.1016/j.virol.2026.110970
What was done
This is a narrative review and perspective evaluating the public health rationale for universal prophylactic vaccination against Epstein-Barr virus (EBV) based on its known associations with infectious mononucleosis, malignancies, and autoimmune diseases.
What was found
The abstract reports no primary experimental data, clinical trial results, or quantitative effect sizes. It notes that EBV infects at least 90% of adults globally and emphasizes that critical questions remain unanswered, particularly whether an EBV vaccine administered after primary infection can protect against chronic EBV-related sequelae.
Why it matters
It outlines the public health argument for prioritizing a universal prophylactic EBV vaccine while identifying critical mechanistic and clinical questions required to optimize implementation.
Limits
The paper is a narrative commentary without original data, systematic review methodology, or quantitative evaluation of candidate vaccine efficacy and safety.
Cited by
- supports Epstein-Barr virus (EBV) infection is etiologically linked to cancers including nasopharyngeal carcinoma.